Overview

"TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This study is designed to look at the effect of Pioglitazone treatment on the body's ability to burn food in order to produce energy.
Phase:
Phase 4
Details
Lead Sponsor:
Pennington Biomedical Research Center
Collaborator:
Takeda Pharmaceuticals North America, Inc.
Treatments:
Pioglitazone